RCKT — ROCKET PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1281895 ·
Last close
$2.63
Market Cap
$288.71M
52W High
$5.45
52W Low
$2.42
ADV30
1,916,497
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -46,922,000 | 123,214,000 | 423,098,000 | 224,507,000 | 54,268,000 |
| Mar 2026 | 0 | — | -48,511,000 | -47,594,000 | 285,407,000 | 49,610,000 | 47,368,000 |
| Dec 2025 | 0 | — | -44,031,000 | -42,538,000 | 330,449,000 | 77,558,000 | 53,228,000 |
| Sep 2025 | 0 | — | -52,419,000 | -50,332,000 | 368,033,000 | 75,948,000 | 54,364,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-179,618,000
Investing CF
$179,250,000
Financing CF
$147,000
CapEx
$-587,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.87
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,488,833,000
Inventory
—
Receivables
—
ST Investments
$94,769,000
EBIT TTM
$-207,491,000
Pretax Income TTM
$-209,383,000
Interest Exp TTM
$1,892,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -228,516,000 | -223,123,000 | 330,449,000 | 53,228,000 | 277,221,000 | -190,014,000 |
| Dec 2024 | 0 | -273,205,000 | -258,746,000 | 527,700,000 | 64,466,000 | 463,234,000 | -209,724,000 |
| Dec 2023 | 0 | -259,659,000 | -245,595,000 | 566,341,000 | 73,767,000 | 492,574,000 | -194,916,000 |
| Dec 2022 | 0 | -223,843,000 | -221,863,000 | 551,807,000 | 62,121,000 | 489,686,000 | -178,142,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-209,383,000
OpCashFlow TTM
—
Assets (Latest)
$285,407,000
Forward EPS
$-1.30
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $2.56 · call oi: 7,228 · put oi: 371
Expected Move to 2026-10-16:
±$0.32
(12.70%) —
implied range
$2.23 –
$2.88
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | $286.11M | $3.75 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $285.44M | $0.26 | — |
| BIOA | BioAge Labs, Inc. | $285.02M | $6.21 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $283.63M | $4.96 | — |
| LRMR | Larimar Therapeutics, Inc. | $280.48M | $2.70 | — |
News headlines (Yahoo Finance, 1h cache)
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
2026-10-07 15:36 · Yahoo
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
2026-10-07 13:36 · Yahoo
Rocket receives $150m credit facility to advance cardiovascular portfolio
2026-10-07 10:42 · Yahoo
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
2026-10-07 02:02 · Yahoo
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
2026-09-22 23:52 · Yahoo
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock
2026-09-16 12:07 · Yahoo
Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial
2026-09-15 14:21 · Yahoo
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights
2026-09-15 14:12 · Yahoo
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
2026-09-15 11:00 · Yahoo
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
2026-09-09 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.